Cell Cycle / Checkpoint Control
| CSTコード |
包装 |
希望納入価格（円） |
国内在庫  |
ご登録代理店情報 カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #2506 | 100 μL | 46,000 | |
|
Cdk5抗体製品一覧
推奨プロトコール
最適な結果を得るために：Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。
推奨プロトコールはCST社内試験の徹底的なバリデーションに基づいて作成されておりますので、正確かつ再現性の高い結果が得られます。
注：各製品に最適化されたプロトコールをリンクしています。
| | |
-
2506:
-
Immunoprecipitation
Western Blotting
| 用途（希釈倍率） | |
| ウエスタンブロッティング(1:1,000)、免疫沈降（1:50） |
| 特異性・感度 | |
| 内在性レベルのCDK5 タンパク質を検出します。 |
| 使用抗原 | |
| ヒトのCDK5 タンパク質（合成ペプチド） |
Western Blotting
Western blot analysis of extracts from PC12 and Jurkat cells, using CDK5 Antibody.
Western Blotting
Western blot analysis of recombinant CDK1-5, using CDK5 Antibody (top) and GST Antibody #2622 (bottom).
Cyclin-dependent kinases (CDKs) are serine/threonine kinases that are activated by cyclins and govern eukaryotic cell cycle progression. While CDK5 shares high sequence homology with its family members, it is thought mainly to function in postmitotic neurons to regulate the cytoarchitecture of these cells. Analogous to cyclins, the regulatory subunits p35 and p39 associate with and activate CDK5 despite the lack of sequence homology. CDK5 is ubiquitously expressed, with high levels of kinase activity detected primarily in the nervous system due to the narrow expression pattern of p35 and p39 in post-mitotic neurons. A large number of CDK5 substrates have been identified although no substrates have been specifically attributed to p35 or p39. Substrates of CDK5 include p35, PAK1, Src, β-catenin, tau, neurofilament-H, neurofilament-M, synapsin1, APP, DARPP32, PP1-inhibitor and Rb. p35 is rapidly degraded (T1/2 <20 min) by the ubiquitin-proteasome pathway (1). However, p35 stability increases as CDK5 kinase activity decreases, likely as a result of decreased phosphorylation of p35 at Thr138 by CDK5 (2). Proteolytic cleavage of p35 by calpain produces p25 upon neurotoxic insult, resulting in prolonged activation of CDK5 by p25. Accumulation of p25 is found in neurodegenerative diseases such as Alzheimer disease and amyotrophic lateral sclerosis (ALS) (3,4).
-
Dhavan, R. and Tsai, L.H. (2001)
Nat Rev Mol Cell Biol
2, 749-59.
-
Patrick, G.N. et al. (1998)
J Biol Chem
273, 24057-64.
-
Lee, M.S. et al. (2000)
Nature
405, 360-4.
-
Kusakawa, G. et al. (2000)
J Biol Chem
275, 17166-72.
